

## COMPANY OVERVIEW

Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius is currently advancing two proprietary product candidates, our Mino-Lok™ product and a hydrocortisone-lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care.

## RECENT NEWS

### Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing

Dec 10 2018, 8:35 AM EST

### Citius Pharmaceuticals to Present at the 11th Annual LD Micro Main Event

Nov 30 2018, 8:00 AM EST

### Citius Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 6

Nov 29 2018, 4:35 PM EST

## STOCK OVERVIEW

Symbol	CTXR
Exchange	Nasdaq
Market Cap	17.66m
Last Price	\$1.09
52-Week Range	\$1.1081 - \$5.29

12/10/2018 04:00 PM EST

## INVESTOR RELATIONS

Andrew Scott  
VP of Investor Relations  
T: 908-967-6677 ext. 105

## MANAGEMENT TEAM

### Myron Holubiak

President, Chief Executive Officer and Director

### Jaime Bartushak

Chief Financial Officer and Principal Financial Officer

### Gary F. Talarico

Executive Vice President, Operations

## CITIUS PHARMACEUTICALS, INC.

11 Commerce Drive, First Floor  
Cranford, NJ 07016  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.